How Reduced HDAC2 Affects Nrf2 in COPD
Author Information
Author(s): Nicolas Mercado, Rajesh Thimmulappa, Catherine M.R. Thomas, Peter S. Fenwick, Kirandeep K. Chana, Louis E. Donnelly, Shyam Biswal, Kazuhiro Ito, Peter J. Barnes
Primary Institution: Imperial College, London
Hypothesis
HDAC2 may control Nrf2 activity via deacetylation, and a decrease in HDAC2 may impair Nrf2 function.
Conclusion
Reduced HDAC2 activity in COPD may lead to increased Nrf2 acetylation, decreased Nrf2 stability, and impaired antioxidant defenses.
Supporting Evidence
- Nrf2 activity is reduced in chronic obstructive pulmonary disease (COPD) due to decreased HDAC2.
- HDAC inhibition leads to increased Nrf2 acetylation and decreased stability.
- Significant correlation between HDAC2 expression and Nrf2 expression was found in monocyte-derived macrophages.
Takeaway
When a protein called HDAC2 is less active, another protein called Nrf2 doesn't work well, which can make it harder for our bodies to fight off damage from things like smoke.
Methodology
The study involved cell culture experiments with BEAS2B cells and monocyte-derived macrophages, along with in vivo experiments in mice exposed to cigarette smoke.
Potential Biases
Potential bias in sample selection from healthy volunteers and COPD patients.
Limitations
The study primarily focused on specific cell lines and animal models, which may not fully represent human conditions.
Participant Demographics
Participants included healthy volunteers, smokers, and COPD patients.
Statistical Information
P-Value
p<0.0001
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website